STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: As reported in New England Journal of Medicine (Oct 30, 2008), Diamyd® preserves insulin producing beta cells best in patients recently diagnosed with the disease. Beta cell destruction is a consecutive process, eventually leading to the need for life-long treatment with insulin. Diamyd® given before clinical presentation could hence prevent the onset of the disease.
